Davidson Michael H.
SEC insider (Form 3/4/5 filer). CIK 0001573785. Chief Executive Officer at NewAmsterdam Pharma Co N.V. (NAMS) and 3 other issuers. 29 reported Form 4/5 transactions since Sep 2024; latest on Sep 14, 2026. Located in NAARDEN.
Companies Davidson Michael H. has filed insider reports for
- NewAmsterdam Pharma Co N.V. (NAMS): Director, Officer, Chief Executive Officer
- BioAge Labs, Inc. (BIOA): Director
- TENAX THERAPEUTICS, INC. (TENX): Director
- Silence Therapeutics plc (SLN): Director
Davidson Michael H.
CIK: 0001573785
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (29 total)
- Sep 14, 2026NAMS
NewAmsterdam Pharma Co N.V.
PurchaseDirect10K shares at avg. $22.65$227K - Jun 10, 2026BIOA
BioAge Labs, Inc.
AwardDirectStock Option (Right to Buy)
22K shares- - Mar 2, 2026NAMS
NewAmsterdam Pharma Co N.V.
SaleDirect443.7K shares at avg. $33.25$14.8M - Mar 2, 2026NAMS
NewAmsterdam Pharma Co N.V.
ExerciseDirect443.7K shares- - Feb 26, 2026NAMS
NewAmsterdam Pharma Co N.V.
SaleDirect165.4K shares at avg. $33.63$5.6M - Feb 26, 2026NAMS
NewAmsterdam Pharma Co N.V.
ExerciseDirect183.3K shares- - Feb 26, 2026NAMS
NewAmsterdam Pharma Co N.V.
SaleDirect17.9K shares at avg. $34.44$617K - Feb 25, 2026NAMS
NewAmsterdam Pharma Co N.V.
SaleDirect46.5K shares at avg. $35.11$1.6M - Feb 25, 2026NAMS
NewAmsterdam Pharma Co N.V.
SaleDirect10.4K shares at avg. $35.96$375K - Feb 25, 2026NAMS
NewAmsterdam Pharma Co N.V.
ExerciseDirect58.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 14, 2026 |  NAMS NewAmsterdam Pharma Co N.V. | Purchase | 10,000 | $22.65 | $226,500 | Direct |
| Jun 10, 2026 |  BIOA BioAge Labs, Inc. | Award Stock Option (Right to Buy) | 22,000 | - | - | Direct |
| Mar 2, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale | 443,707 | $33.25 | $14,753,258 | Direct |
| Mar 2, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise | 443,707 | - | $0 | Direct |
| Feb 26, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale | 165,408 | $33.63 | $5,562,671 | Direct |
| Feb 26, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise | 183,332 | - | $0 | Direct |
| Feb 26, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale | 17,924 | $34.44 | $617,303 | Direct |
| Feb 25, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale | 46,517 | $35.11 | $1,633,212 | Direct |
| Feb 25, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale | 10,436 | $35.96 | $375,279 | Direct |
| Feb 25, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise | 58,253 | - | $0 | Direct |
1-10 of 29 transactions